Entrada Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Entrada Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Entrada Therapeutics Inc
Rating: 1.32408325
Author: Trendlyne DVM scores

about

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosoma...

5.38 -0.09 (-1.65%)

75.31% Fall from 52W High

284.9K

XNAS Volume

XNAS 02 Sep, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

27.3 / 100

Technically Bearish

25.6 / 100

1Yr Price target upside is 244%

2 analysts

Entrada Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Entrada Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosoma...

75.31% Fall from 52W High

SWOT Analysis

Entrada Therapeutics Inc Live Price Chart